Fixed combination drug therapy
- PMID: 7049658
- DOI: 10.2165/00003495-198223060-00003
Fixed combination drug therapy
Abstract
Almost half of all marketed drugs are fixed combination preparations, yet the World Health Organization included only 7 in its list of 240 "essential' drugs. There has been little scientific study of these preparations but much emotion and rhetoric has been expended both for and against them. Potential advantages of fixed combination preparations include: increased compliance, synergy and increased efficacy, and reduced side effects and cost. Potential disadvantages include: inflexible fixed dose ratio, incompatible pharmacokinetics, increased toxicity, and physician and pharmacist ignorance of content. There are a few combinations of undisputed value such as oral contraceptives, levodopa with decarboxylase inhibitors, and pyrimethamine with sulphadoxine. In other cases fixed-dose combinations may have value in strictly specified circumstances, but are probably overprescribed. There is also widespread, unjustified use of combinations in over-the-counter preparations which may have unrecognised adverse effects. Combinations should only be used if each component is necessary for the desired effect and if the advantages outweigh the added risks of using 2 or more drugs. Before prescribing combination drugs, clinicians should always ask themselves a series of questions of which the most important is whether the patient needs each drug in a particular combination, or if 1 component alone would be adequate. In general, government regulatory bodies in "developed' countries are attempting to curb the use of combination drugs, but a more profitable approach might be to better educate doctors on both the advantages and disadvantages of fixed combination preparations leading to improved prescribing habits.
Similar articles
-
Report of a workshop on fixed-ratio drug combinations.Eur J Clin Pharmacol. 1975 Feb 28;8(2):149-54. doi: 10.1007/BF00561565. Eur J Clin Pharmacol. 1975. PMID: 823031 No abstract available.
-
Fixed-dose combination therapy with statins: strengths, limitations, and clinical and regulatory considerations.Am J Cardiovasc Drugs. 2008;8(3):155-60. doi: 10.2165/00129784-200808030-00002. Am J Cardiovasc Drugs. 2008. PMID: 18533736
-
Using fixed-dose combination therapies to achieve blood pressure goals.Clin Drug Investig. 2008;28(11):713-34. doi: 10.2165/00044011-200828110-00005. Clin Drug Investig. 2008. PMID: 18840014 Review.
-
Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.Drugs. 2002;62(3):443-62. doi: 10.2165/00003495-200262030-00003. Drugs. 2002. PMID: 11827559 Review.
-
Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same?Am J Cardiovasc Drugs. 2007;7(6):413-22. doi: 10.2165/00129784-200707060-00004. Am J Cardiovasc Drugs. 2007. PMID: 18076208 Review.
Cited by
-
Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.Eur J Clin Pharmacol. 1984;26(6):663-8. doi: 10.1007/BF00541922. Eur J Clin Pharmacol. 1984. PMID: 6092093
-
Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians.Drug Des Devel Ther. 2018 Apr 6;12:787-794. doi: 10.2147/DDDT.S145339. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 29670335 Free PMC article. Clinical Trial.
-
Novel Curcumin-Resveratrol Solid Nanoparticles Synergistically Inhibit Proliferation of Melanoma Cells.Pharm Res. 2021 May;38(5):851-871. doi: 10.1007/s11095-021-03043-7. Epub 2021 May 12. Pharm Res. 2021. PMID: 33982225
-
Efficacy of Microneedling and CO2 Laser for Acne Scar Remodelling: A Comprehensive Review.Cureus. 2024 Feb 27;16(2):e55092. doi: 10.7759/cureus.55092. eCollection 2024 Feb. Cureus. 2024. PMID: 38558661 Free PMC article. Review.
-
Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment.Pharmaceuticals (Basel). 2022 Mar 10;15(3):338. doi: 10.3390/ph15030338. Pharmaceuticals (Basel). 2022. PMID: 35337136 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources